Screener
Supernus Pharmaceuticals SUPN Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Employee taxes paid related to net share settlement of equity awards | (4,555) | (3,341) |
| Payment of contingent consideration | — | (20,100) |
| Net cash provided by (used in) financing activities | 9,115 | (21,399) |
| Net change in cash, cash equivalents, and restricted cash | 56,421 | 46,517 |
| Cash and cash equivalents at beginning of year | 129,898 | 69,331 |
| Cash, cash equivalents, and restricted cash at end of year | $186,319 | $115,848 |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $184,869 | $115,848 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's net change in cash?
- Supernus Pharmaceuticals (SUPN) reported net change in cash of $56.42M in Q1 2026.
- How has Supernus Pharmaceuticals's net change in cash changed year-over-year?
- Supernus Pharmaceuticals's net change in cash increased by 21.3% year-over-year, from $46.52M to $56.42M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Supernus Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude